Update shared on19 Aug 2025
Fair value Decreased 24%The downward revision in Milestone Scientific’s price target reflects materially lower revenue growth expectations, leading to a drop in projected fair value from $2.12 to $1.62.
What's in the News
- Eric C. Hines appointed CEO, bringing 25+ years' experience in scaling sales-driven enterprise software, with a record of revenue growth and commercial expansion in healthcare and related industries.
- Initiated commercial sales of CompuFlo Epidural System at The Painless Center in New Jersey, signaling expanded adoption and presence in the interventional pain market.
- CompuFlo system’s proprietary technology offers real-time feedback, improving efficacy and safety in epidural procedures, and has gained attention from respected physicians and institutions.
Valuation Changes
Summary of Valuation Changes for Milestone Scientific
- The Consensus Analyst Price Target has significantly fallen from $2.12 to $1.62.
- The Consensus Revenue Growth forecasts for Milestone Scientific has significantly fallen from 25.5% per annum to 15.0% per annum.
- The Future P/E for Milestone Scientific has fallen from 102.16x to 94.13x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.